GE readies new Logiq alpha line
GE Medical Systems of Milwaukee is preparing for the commercialintroduction of two new ultrasound scanners, the first membersof a new Logiq alpha family of analog black-and-white systemsfor the entry-level and mid-range segments.Designed and produced by
GE Medical Systems of Milwaukee is preparing for the commercialintroduction of two new ultrasound scanners, the first membersof a new Logiq alpha family of analog black-and-white systemsfor the entry-level and mid-range segments.
Designed and produced by GEMS India, Logiq alpha 100 is a small,portable scanner that features a software-controlled architecturewith continuously adjusted dynamic focus for echo-sensitive, 256-shadegray-scale images, according to the company. GE included informationabout the scanner in its press kit at this month's European Congressof Radiology meeting in Vienna.
Logiq alpha 100 weighs 9.8 kg and is compatible with advancedconvex and microconvex probes. The system is suitable for a widerange of studies, including ob/gyn, gastroenterology, and urology,according to GE.
GE's Japanese subsidiary, YMS, has started sales of both Logiqalpha 100 and another new member of the Logiq alpha series, Logiqalpha 200, according to Comline News Service. Logiq alpha 200features an aperture area for wave emission and reception 1.7times as wide as conventional systems. Logic alpha 200 receivedFood and Drug Administration clearance in August 1996.
As of press time, GE ultrasound executives could not be reachedfor comment on whether the Logiq alpha line will be sold in theU.S.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
